CN108431003A - 含有吲哚衍生物的药物组合物、其制备方法和用途 - Google Patents

含有吲哚衍生物的药物组合物、其制备方法和用途 Download PDF

Info

Publication number
CN108431003A
CN108431003A CN201680074239.0A CN201680074239A CN108431003A CN 108431003 A CN108431003 A CN 108431003A CN 201680074239 A CN201680074239 A CN 201680074239A CN 108431003 A CN108431003 A CN 108431003A
Authority
CN
China
Prior art keywords
compound
pharmaceutical composition
cancer
dihydrochloride
precipitate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680074239.0A
Other languages
English (en)
Chinese (zh)
Inventor
S·林德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vivolux AB
Original Assignee
Vivolux AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivolux AB filed Critical Vivolux AB
Publication of CN108431003A publication Critical patent/CN108431003A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
CN201680074239.0A 2015-12-18 2016-12-10 含有吲哚衍生物的药物组合物、其制备方法和用途 Pending CN108431003A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1500520 2015-12-18
SE1500520-0 2015-12-18
PCT/EP2016/025175 WO2017102097A1 (en) 2015-12-18 2016-12-10 Pharmaceutical composition comprising indole derivatives, process for preparation and use thereof

Publications (1)

Publication Number Publication Date
CN108431003A true CN108431003A (zh) 2018-08-21

Family

ID=58231562

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680074239.0A Pending CN108431003A (zh) 2015-12-18 2016-12-10 含有吲哚衍生物的药物组合物、其制备方法和用途

Country Status (14)

Country Link
US (1) US10668056B2 (enExample)
EP (1) EP3390403B1 (enExample)
JP (2) JP6929299B2 (enExample)
CN (1) CN108431003A (enExample)
AU (1) AU2016371541B2 (enExample)
CA (1) CA3008084A1 (enExample)
DK (1) DK3390403T3 (enExample)
EA (1) EA039778B1 (enExample)
ES (1) ES2925690T3 (enExample)
HK (1) HK1257129A1 (enExample)
HU (1) HUE059610T2 (enExample)
PL (1) PL3390403T3 (enExample)
PT (1) PT3390403T (enExample)
WO (1) WO2017102097A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016371541B2 (en) * 2015-12-18 2021-07-08 Vivolux Ab Pharmaceutical composition comprising indole derivatives, process for preparation and use thereof
WO2021044608A1 (ja) * 2019-09-06 2021-03-11 シミックホールディングス株式会社 ダントロレン水性製剤及びその調製方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006102102A2 (en) * 2005-03-17 2006-09-28 Marshfield Clinic Tgf-beta modulators and methods for using the same
CN103547268A (zh) * 2011-03-21 2014-01-29 威沃路克斯股份公司 实体瘤的治疗
CN104662022A (zh) * 2012-09-21 2015-05-27 威沃路克斯股份公司 治疗实体瘤的手段和方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660737B2 (en) * 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
WO2009035534A2 (en) * 2007-09-07 2009-03-19 The Cleveland Clinic Foundation Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
AU2016371541B2 (en) * 2015-12-18 2021-07-08 Vivolux Ab Pharmaceutical composition comprising indole derivatives, process for preparation and use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006102102A2 (en) * 2005-03-17 2006-09-28 Marshfield Clinic Tgf-beta modulators and methods for using the same
CN103547268A (zh) * 2011-03-21 2014-01-29 威沃路克斯股份公司 实体瘤的治疗
CN104662022A (zh) * 2012-09-21 2015-05-27 威沃路克斯股份公司 治疗实体瘤的手段和方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
XIAONAN ZHANG ET AL.: "Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments", 《NATURE COMMUNICATIONS》 *
赵广荣 等: "《现代生命科学与生物技术》", 31 October 2008, 天津大学出版社 *

Also Published As

Publication number Publication date
JP6929299B2 (ja) 2021-09-01
HK1257129A1 (zh) 2019-10-11
AU2016371541B2 (en) 2021-07-08
EP3390403A1 (en) 2018-10-24
CA3008084A1 (en) 2017-06-22
HUE059610T2 (hu) 2022-12-28
EA039778B1 (ru) 2022-03-14
US20180280366A1 (en) 2018-10-04
AU2016371541A1 (en) 2018-06-07
ES2925690T3 (es) 2022-10-19
JP2021130673A (ja) 2021-09-09
JP2019505571A (ja) 2019-02-28
EP3390403B1 (en) 2022-06-29
PL3390403T3 (pl) 2022-10-24
US10668056B2 (en) 2020-06-02
PT3390403T (pt) 2022-09-06
WO2017102097A1 (en) 2017-06-22
DK3390403T3 (da) 2022-08-29
EA201891027A1 (ru) 2019-02-28

Similar Documents

Publication Publication Date Title
CN109563100B (zh) 三唑并嘧啶化合物的晶体形式
TWI259081B (en) Treatment of acute myeloid leukemia with indolinone compounds
CN116507620B (zh) Cdk4抑制剂的固体形式
KR102342776B1 (ko) (S)-2-((2-((S)-4-(다이플루오로메틸)-2-옥소옥사졸리딘-3-일)-5,6-다이하이드로벤조[f]이미다조[1,2-d][1,4]옥사제핀-9-일)아미노)프로판아미드의 다형체 및 고체 형태, 및 이의 제조 방법
TWI415613B (zh) Anti-cancer agent resistance to overcome the agent
CN112010839B (zh) 靶向丝/苏氨酸激酶抑制剂的晶型
JP2021130673A (ja) インドール誘導体を含む医薬組成物、その調製方法及びその使用
US11865095B2 (en) Combination drug substance of polyamine transport inhibitor and DFMO
JP6073480B2 (ja) ＰＩ３Ｋおよび／またはｍＴＯＲ阻害剤
EP4631937A1 (en) Crystalline form or amorphous form of oxoisoindole-5-formamide compound or salt and solvate thereof
KR101995533B1 (ko) [1,2,4]트리아졸로[4,3-a]퀴노잘린 아미노 페닐 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 BET 단백질 관련 질환의 예방 또는 치료용 약학적 조성물
WO2024040241A1 (en) Pharmaceutical formulations, processes for preparation, and methods of use
JP2025527820A (ja) キノリン誘導体阻害剤の結晶形、及びその調製方法並びに用途
RU2419431C1 (ru) ПРОИЗВОДНЫЕ β-КАРБОЛИНА, ОБЛАДАЮЩИЕ ПРОТИВОТУБЕРКУЛЕЗНОЙ АКТИВНОСТЬЮ, ИХ ПРИМЕНЕНИЯ ДЛЯ ПРОИЗВОДСТВА ЛЕКАРСТВЕННОГО СРЕДСТВА, СПОСОБ ИХ СИНТЕЗА, А ТАКЖЕ НОВЫЕ МЕТОДЫ ЛЕЧЕНИЯ С ИХ ИСПОЛЬЗОВАНИЕМ
TW201406377A (zh) 抗癌劑之抗性克服劑
BR112018076443B1 (pt) Processo de preparação de formas cristalinas de um composto de triazolopirimidina
BR122024009277A2 (pt) Formas cristalinas de um composto de triazolopirimidina
HK40020487A (en) Polymorphs and solid forms of gdc-0077, and methods of production thereof
HK1210464B (en) Pi3k and/or mtor inhibitor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1257129

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180821

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1257129

Country of ref document: HK